Olivia Vizier

TFF Pharmaceuticals is on the hunt for new partners, and a recently-announced agreement with Catalent could help them land just that.

Executive president of MindMed, Miri Halperin Wernli, PhD, added: “LSD and psilocybin have recently become promising candidates for the treatment of various psychiatric and neurologic disorders, and thus a deeper understanding of their differential subjective effects in humans is needed. 

Cerevance has developed its proprietary, Nuclear Enriched Transcript Sort sequencing (NETSseq) platform to analyze postmortem human brain tissues to produce rich cell type–specific data sets. 

Portage Biotech: Clinical-stage oncology company dedicated to sourcing and acquiring the most promising early-stage assets available to build a pipeline of first-in-class/best-in-class therapeutic candidates. Currently, has well-established partnerships with both Bristol Myers Squibb and Merck.

Teclison, a Princeton, NJ-based clinical-stage biotechnology company developing innovative cancer therapeutics to induce tumor necrosis and enhance anti-tumor immunity, closed a $5.9m funding round.

The FDA has granted investigational device exemption to medical diagnostics company Check-Cap for a two-part pivotal study to evaluate C-Scan, a new screening test that detects precancerous polyps.

There are currently no approved treatments for the prevention of recurrent VVC, but Scynexis said it will submit the new phase 3 data to the FDA in the first half of 2022 and expects that ibrexafungerp tablets will be approved for this indication by the end of the year.

Cancer intervention and prevention company Check Cap is developing new, low-invasive ingestible capsule technology that aims to address issues associated with preventive screenings for colonoscopies.

As Glenn Mattes, CEO of TFF Pharmaceuticals, told BioSpace, “The persistent rise of COVID-19 cases, including among the vaccinated, has understandably impacted the morale of both the biopharma industry and the broader community.”

MeiraGTx Holdings PLC said it received a $30 million payment from Janssen Pharmaceuticals Inc., part of the Janssen Pharmaceutical Cos. of Johnson & Johnson, for a clinical milestone in a Phase 3 trial of botaretigene sparoparvovec.

The US Food and Drug Administration has cleared an Investigational New Drug application allowing MindMed to move forward with a phase 2b dose-optimization trial of MM-120 for the treatment of generalized anxiety disorder (GAD).

To address both of these challenges, TFF Pharmaceuticals has developed a process called Thin Film Freezing (TFF), which produces drugs that are highly soluble and stable in a powder form, for a variety of applications, including delivery to the lung. 

Recce’s lead drug candidate, called R327, is a synthetic polymer that is currently undergoing Phase I trials for sepsis, with an ongoing Phase I/II trial for burn wound infections. According to Graham, R327 utilizes multiple inhibitory mechanisms that work in “a synergistic compounding fashion.” These mechanisms include adenosine triphosphate (ATP) inhibition, cell membrane permeabilization and

San Jose-based Anixa Biosciences is looking to keep “retired” proteins from coming back and causing havoc to the body—particularly in the form of triple-negative breast cancer and ovarian cancer.

You also need to be strong in other parts of your body if you want to keep active. In your knees, you need to maintain strength, but also flexibility and muscular balance, says Fred Cushner, M.D., an orthopedic surgeon at the Hospital for Special Surgery in New York City and chief medical officer for Canary

Another company, Renovacor, is looking beyond oncology to cardiology – specifically to dilated cardiomyopathy. Its precision gene replacement therapy targets patients with mutations in the BAG3 gene that causes lower levels of BAG3 in the heart. “We want to boost levels of BAG3 in the heart to address the root cause of this aggressive disease,” Matt

Lee-Sepsick founded Femasys 18 years ago, after executive positions at two other biotechs.

“All of a sudden, almost every person in the world almost knows this word: mRNA,” said Yochi Slonim, co-founder and CEO of Anima Biotech, a New Jersey-based company developing selective small-molecule mRNA drugs with its mRNA Lightning platform. 

A: Our greatest impact will be in the field of psychiatry, due to our bringing a precision medicine approach to the field for the first time. Today, psychiatric treatment only works for roughly one in three patients. 

Portage Biotech is leveraging its team’s longstanding experience in immuno-oncology (members have contributed to the development of several approved and in development CPIs) and treatment resistance to develop a series of novel combinations to help those not responding to the SOC. 

Ring’s research team has uncovered and characterized the world’s largest collection of commensal anelloviruses and is harnessing those best suited for specifically targeting a wide array of diseases with significant unmet needs. The unique biology of anelloviruses may indeed provide a foundation for an unparalleled new gene therapy platform and the resulting new class of

At just 10 months out of stealth, gene-editing startup SalioGen Therapeutics has lassoed a $115 million round with plans to double its team, build out its drug pipeline and move to a new, expanded facility.

As 2022 begins, Aptinyx is laying the groundwork to transition to a late-stage clinical, and one day commercial, company. At the same time, its senior leadership also is transitioning into new roles. Andy Kidd, M.D., takes on the role of CEO after stints as Aptinyx’s president and chief operating officer, and before that, chief commercial officer. Norbert

It was late 2015 when Lara Sullivan, M.D., first called me. At the time she was a VP at Pfizer and working closely with Freda Lewis-Hall, M.D., then the company’s chief medical officer. From their vantage point, they could see this tremendous pipeline flow of assets—along with what got funded — and what did not.

Mental health startup Cerebral has inked a partnership with Alto Neuroscience to bring clinical trials for depression to patients’ homes.

When she helped start MeiraGTx Holdings in 2015, CEO Zandy Forbes wanted to find a way to precisely control the output of genes implanted in people to fix genetic disorders. In an analyst meeting Wednesday, MeiraGTx unveiled that technology.

Scynexis sees a $300m-$400m commercial opportunity for the supplemental indication. A new therapeutic option is needed for oral step-down therapy because many Candida infections are resistant to oral fluconazole.

Douglas W. Blayney, MD, is a professor of medicine (oncology) at Stanford University and the former Medical Director of Stanford Cancer Center. He specializes in breast cancer treatment. He is particularly concerned about the quality and value of cancer care. In this video Dr. Blayney discusses the Phase 3 PROTECTIVE-2 TRIAL.